The Arthroscopic Surgery Unit (UCA) has initiated a clinical study to analyze the impact of extreme fatigue on the regenerative capacity of triathletes, by analyzing plasma markers before and after their participation in the ‘vi half Gasteiz’ triathlon. The aim is to generate scientific evidence to optimize recovery times and prevent injuries resulting from overtraining in highly demanding sports.

A recent study demonstrates that Platelet Rich Plasma (PRP) maintains its bioactivity after 6 and 12 months of freezing at -20 °C and -80 °C, supporting its deferred clinical use and medical biobanking.

This study reveals how sex, the use of PRP, and genetic variants influence the risk of developing arthrofibrosis after anterior cruciate ligament reconstruction. It includes a predictive model to identify high-risk patients and improve surgical outcomes.

More than 40 international experts met in Vitoria-Gasteiz on the occasion of the I MiKS Congress, with the aim of strengthening scientific consensus and highlighting the potential of biological therapies in the field of regenerative medicine. During the meeting, key advances in areas such as cellular aging, chronic inflammation and tissue regeneration were addressed.

From April 3 to 5, 2025, Vitoria-Gasteiz will be the meeting point for the main international references in biological therapies. This congress will bring together experts in orthopedic surgery, sports medicine and pain management, among others, to explore the latest advances in blood derivatives and cell therapies. 

Peripheral nerve injuries (PNI) are common, with more than one million cases annually worldwide, resulting in loss of motor and sensory function and muscle atrophy due to prolonged denervation.

This development represents a crucial step towards more effective and personalized treatments in the field of tissue regeneration.

Biological therapies are booming and more of these formulations are coming to the market as well as novel systems for the production of PRPs. 

The Clinical Trials Information System (CTIS), managed by the European Medicines Agency (EMA), has been updated to allow earlier and more efficient access to information on clinical trials in the EU.

Analyzing 32 studies in animal models (1079 joints), it was found that CS injections showed positive effects in 68% of the studies and detrimental effects in 16%.

This international award recognizes all those who have worked tirelessly for the development, preservation and advancement of Regenerative Medicine through their leadership, clinical research and dedication.